Beijing Anzhen Hospital
首都医科大学附属北京安贞医院
Listed for 13 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Beijing Anzhen Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌6 papers led
- Osteosarcoma骨肉瘤1 paper led
- Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
- Beta thalassaemiaβ 地中海贫血0 papers led
- IgG4-related diseaseIgG4相关性疾病0 papers led
- Takayasu arteritis大动脉炎30 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
- Fabry disease法布雷病0 papers led
- Behçet disease白塞病2 papers led
- Alport syndromeAlport 综合征1 paper led
- IgA nephropathyIgA 肾病3 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 6 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Beijing for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- METTL3-mediated m 6A modification facilitates Nectin-4-induced VNN1 upregulation and promotion of ESCC progression.
- CircSLC22A3 inhibits the invasion and metastasis of ESCC via the miR-19b-3p/TRAK2 axis and by reducing the stability of m6A-modified ACSBG1 mRNA.
- Transcription factor SPI1 exacerbates the malignant progression of esophageal squamous cell carcinoma byactivating LAMA3 expression.
- LINC01305 and LAD1 Co-Regulate CTTN and N-WASP Phosphorylation, Mediating Cytoskeletal Reorganization to Promote ESCC Metastasis.
- WTAP-mediated m6A methylation of circRNA_404908 promotes esophageal squamous cell carcinoma progression.
- Plasma CircCYP24A1 as a Novel Biomarker of Esophageal Squamous Cell Carcinoma.
Cancer
Osteosarcoma
骨肉瘤Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
37 hospitals in Beijing for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
19 hospitals in Beijing for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
- Assessing the effectiveness of etoposide treatment in adult haemophagocytic lymphohistiocytosis: a systematic review and meta-analysis.
- Chimeric antigen receptor T cell immunotherapy‑associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review).
Chinese-language papers (not in the count)1
Blood disorders
Beta thalassaemia
β 地中海贫血Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Beijing for beta thalassaemia133 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
IgG4-related disease
IgG4相关性疾病Led no English-language PubMed papers on IgG4-related disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Other diseases
Takayasu arteritis
大动脉炎Led 30 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 16.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
24 hospitals in Beijing for Takayasu arteritis100 hospitals in China for Takayasu arteritis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)
- Phase
- Not given
- Started
- 2016-01
- Registry
- NCT03372980
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led30
- ANK2-MAVS signaling dysfunction triggers mitochondrial stress and enhances IL-8 mediated inflammatory responses in Takayasu arteritis.
- Integrated bulk and single-cell transcriptomics identifies shared and specific immune signatures in Takayasu Arteritis.
- Single-cell transcriptome analysis reveals cellular heterogeneity in the aortas of Takayasu arteritis.
- Acute left heart failure is the initial manifestation of Takayasu arteritis: a case report.
- CD8 cell-derived granzyme B may be a predictor for coronary artery involvement and MACE in Takayasu arteritis patients.
- Elevated serum uric acid is a predictor of pulmonary artery involvement and subsequent prognosis in patients with Takayasu's arteritis.
- The role of granulocyte colony-stimulating factor in Takayasu arteritis.
- Coronary artery calcification in Takayasu's arteritis: clinical characteristics and risk factors.
- Elevated serum 25-hydroxyvitamin D: a potential indicator of remission in Takayasu arteritis patients with normal ESR and CRP levels.
- Right Ventricular Function in Takayasu's Arteritis Patients With Pulmonary Artery Involvement Using MRI Feature Tracking.
- Elevated serum immunoglobulin level predicts high risk of 1-year recurrence in patients with Takayasu arteritis.
- Predictors for pulmonary artery involvement in Takayasu arteritis and its cluster analysis.
- PD-1 Deficiency in Regulatory T Cells May be Involved in the Pathogenesis of Takayasu's Arteritis.
- Characteristics of B cells and immunoglobulin profile in Takayasu's arteritis.
- High-throughput sequencing reveals the change of TCR α chain CDR3 with Takayasu arteritis.
- Biomarkers in Takayasu arteritis.
- Anaemia can be improved by controlling the disease activity of Takayasu's arteritis without iron administration.
- Platelet count as a potential predictor in refractory Takayasu arteritis.
- Risk factors and surgical prognosis in patients with aortic valve involvement caused by Takayasu arteritis.
- Five-year outcome with revascularisation therapy in Takayasu arteritis with multiple coronary involvement: a case review.
- Association of Prolonged Disease Duration and TG/HDL-C Ratio in Accelerating Atherosclerosis in Patients with Takayasu's Arteritis.
- Clinical features and risk factors of intracranial artery disease in patients with Takayasu arteritis.
- The role of CD8+ Granzyme B+ T cells in the pathogenesis of Takayasu's arteritis.
- Male Patients with Takayasu Arteritis and Coronary Artery Involvement are Prone to Have Serious Coronary Stenosis and High Mortality.
- Quantification of Myocardial Deformation in Patients with Takayasu Arteritis by Cardiovascular Magnetic Resonance Feature Tracking Imaging.
- Plasma proteomic screening and validation of novel biomarkers in Takayasu's arteritis.
- Cardiac valvular involvement of Takayasu arteritis.
- Pulmonary artery involvement in Takayasu arteritis: a retrospective study in Chinese population.
- Serum concentrations of small dense low-density lipoprotein cholesterol and lipoprotein(a) are related to coronary arteriostenosis in Takayasu arteritis.
- CD8+ T lymphocyte is a main source of interferon-gamma production in Takayasu's arteritis.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)19
- Elevated antistreptolysin O titer is closely related to cardiac mitral insufficiency in untreated patients with Takayasu arteritis.
- Association of interleukin-18 gene polymorphisms with Takayasu arteritis in a Chinese Han population.
- Natural killer cells and their function in Takayasu's arteritis.
- Contribution of Th2-like Treg cells to the pathogenesis of Takayasu's arteritis.
- Numano type V Takayasu arteritis patients are more prone to have coronary artery involvement.
- Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis.
- Comparison of Clinical Features at the Onset of Takayasu's Arteritis According to Age and Sex.
- The relationships of serum homocysteine levels and traditional lipid indicators with disease activity and coronary artery involvement in Takayasu arteritis.
- T-614 inhibits human aortic adventitial fibroblast proliferation and promotes interleukin-8 production in vitro.
- [Clinical features of intracranial vessel involvement in Takayasu's arteritis].
- Treatment with Corticosteroid and/or Immunosuppressive Agents before Surgery can Effectively Improve the Surgical Outcome in Patients with Takayasu's Arteritis.
- Takayasu Arteritis with Dyslipidemia Increases Risk of Aneurysm.
- [Efficacy and safety of tocilizumab in patients with Takayasu arteritis].
- [Relationships between the levels of serum 25-hydroxyvitamin D and interleukin-6 in patients with Takayasu's arteritis].
- Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio associated with disease activity in patients with Takayasu's arteritis: a case-control study.
- Relationship of HLA-B*51 and HLA-B*52 alleles and TNF-α-308A/G polymorphism with susceptibility to Takayasu arteritis: a meta-analysis.
- IL-9-producing Th9 cells may participate in pathogenesis of Takayasu's arteritis.
- Sonographic Characterization of Arterial Dissections in Takayasu Arteritis.
- [Clinical data analysis of valvular involvement in Takayasu arteritis].
All its trials on ClinicalTrials.gov, any status4
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
25 hospitals in Beijing for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)3
- IL-25/IL-33/TSLP contributes to idiopathic pulmonary fibrosis: Do alveolar epithelial cells and (myo)fibroblasts matter?
- IL-25 contributes to lung fibrosis by directly acting on alveolar epithelial cells and fibroblasts.
- Incidence and radiologic-pathological features of lung cancer in idiopathic pulmonary fibrosis.
Other diseases
Fabry disease
法布雷病Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Beijing for Fabry disease80 hospitals in China for Fabry disease
No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Behçet disease
白塞病Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
19 hospitals in Beijing for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)7
- [Cardiologists' perceptions on Behcet's disease and its cardiovascular lesions: a single center analysis].
- Echocardiographic features of interventricular septal dissection in patients with Behçet's disease.
- Echocardiographic findings of cardiovascular involvement in Behçet's disease and post-operative complications after cardiac surgery.
- Clinical characteristics of conduction disturbance in patients with Behcet's disease.
- Characteristic Echocardiographic Manifestations of Behçet's Disease.
- A giant pseudoaneurysm of coronary artery in a young patient with Behçet's disease.
- [Clinical data analysis of cardiovascular involvement in Behcet's disease].
Other diseases
Alport syndrome
Alport 综合征Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Beijing for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
25 hospitals in Beijing for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Warfarin-related nephropathy: unveiling the hidden dangers of anticoagulation.
- Complement system is overactivated in patients with IgA nephropathy after COVID-19.
- Glomerular Galactose-Deficient IgA1(KM55) Positive May Predict Poorer Prognosis in Coexisting Primary Membranous Nephropathy and IgA Nephropathy Patients.
All its trials on ClinicalTrials.gov, any status3
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Beijing for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Getting in touch
Name card to show staff or a driver
首都医科大学附属北京安贞医院
Beijing Anzhen Hospital
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR Wikidata
Beijing Anzhen Nanchong Hospital; Beijing Anzhen Nanchong Hospital of Capital Medical University; Capital Medical University Affiliated Beijing Anzhen Hospital; Beijing AnZhen Hospital; Beijing Anzhen Hospital Affiliated to the Capital Medical University; 北京市心肺血管疾病研究所